Ryan K. Shields - Concepedia

Author

Ryan K. Shields

Also Known As

R K Shields, R Shields, R. K. Shields, R. Shields, R.K. Shields, Ryan K. Shields, Ryan K Shields, Ryan K. Shields, Ryan Shields, Shields, Ryan

314

Publications

9.9K

Citations

H-Index

Concepts

All Affiliations

University of Pittsburgh University of Pittsburgh Medical Center VA Pittsburgh Healthcare System Rutgers, The State University of New Jersey Fujita Health University

About

Ryan K. Shields is an author at University of Pittsburgh specializing in medicine, antimicrobial resistance, and clinical microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	34	2.1K
2	Health Sciences	18	20	1.5K
3	Humanities	1	1	15
4	Natural Sciences	1	1	57
5	Public Health	1	1	23

Ryan K. Shields

129

Publications

9.2K

Citations

H-Index

Page 1

	Year	Citations
Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> <sub>KPC-3</sub> Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections Ryan K. Shields, Liang Chen, Shaoji Cheng, Antimicrobial Agents and Chemotherapy	2016	476
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia Ryan K. Shields, M. Hong Nguyen, Liang Chen, Antimicrobial Agents and Chemotherapy	2017	472
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1. Ryan K. Shields, Brian A. Potoski, Ghady Haidar, Clinical Infectious Diseases Cre InfectionsAntimicrobial ChemotherapyAntibiotic ResistanceDrug ResistanceClinical Outcomes	2016	417
Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance Zubair Qureshi, Lauren Hittle, Jessica A. O’Hara, Clinical Infectious Diseases	2015	394
Performance of Candida Real-time Polymerase Chain Reaction, -D-Glucan Assay, and Blood Cultures in the Diagnosis of Invasive Candidiasis M. Hong Nguyen, Mark Wissel, Ryan K. Shields, Clinical Infectious Diseases	2012	288
Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections Ryan K. Shields, M. Hong Nguyen, Liang Chen, Antimicrobial Agents and Chemotherapy	2018	278
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance Ghady Haidar, Nathan J Philips, Ryan K. Shields, Clinical Infectious Diseases	2017	265
Mutations in<i>bla</i><sub>KPC-3</sub>That Confer Ceftazidime-Avibactam Resistance Encode Novel KPC-3 Variants That Function as Extended-Spectrum β-Lactamases Ghady Haidar, Cornelius J. Clancy, Ryan K. Shields, Antimicrobial Agents and Chemotherapy	2017	189
The Presence of an <i>FKS</i> Mutation Rather than MIC Is an Independent Risk Factor for Failure of Echinocandin Therapy among Patients with Invasive Candidiasis Due to Candida glabrata Ryan K. Shields, M. Hong Nguyen, Ellen G. Press, Antimicrobial Agents and Chemotherapy	2012	170
Intra-Abdominal Candidiasis: The Importance of Early Source Control and Antifungal Treatment Pascalis Vergidis, Cornelius J. Clancy, Ryan K. Shields, PLoS ONE	2016	144

Page 1